| Identification | Back Directory | [Name]
Pimodivir | [CAS]
1629869-44-8 | [Synonyms]
VX-787
CS-2483
Pimodivir
VRT0928787
VRT-0928787
VRT 0928787
Pimodivir (VX-787)
VX-787 (Pimodivir)
VX-787; VX 787; VX787; JNJ-872; JNJ 872; JNJ872; VRT-0928787; VRT 0928787; VRT0928787;PIMODIVIR
(2S,3S)-3-[[5-Fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-pyrimidinyl]amino]bicyclo[2.2.2]octane-2-carboxylic acid
Bicyclo[2.2.2]octane-2-carboxylic acid, 3-[[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-pyrimidinyl]amino]-, (2S,3S)- | [Molecular Formula]
C20H19F2N5O2 | [MDL Number]
MFCD31382121 | [MOL File]
1629869-44-8.mol | [Molecular Weight]
399.39 |
| Chemical Properties | Back Directory | [density ]
1.501±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO, not in water:100.0(Max Conc. mg/mL);250.38(Max Conc. mM) | [form ]
A solid | [pka]
4.32±0.40(Predicted) |
| Hazard Information | Back Directory | [Description]
Pimodivir is an inhibitor of influenza virus polymerase basic protein 2 (PB2; KD = <0.003 μM). It also binds to glycogen synthase kinase 3β (GSK3β; Ki = ~1.6 μM) and inhibits the activity of Axl and calcium/calmodulin-dependent protein kinase IIβ (CaMKIIβ) by greater than 50% in a panel of 65 human and rat kinases. Pimodivir decreases the replication of seven adamantine- and neuraminidase inhibitor-resistant strains of influenza virus A (EC50s = <0.15-2.8 nM in a cell-based assay). It increases the antiviral activity of oseltamivir , zanamivir , and favipiravir (T-705; ) with 50% combination index (CI50) values of 0.58, 0.64, and 0.89, respectively, in a cell-based assay. Pimodivir increases survival in a mouse model of intranasal influenza A infection when administered at doses of 1, 3, and 10 mg/kg twice per day. | [Uses]
Pimodivir is an orally bioavailable azaindole inhibitor of influenza PB2. | [storage]
Store at -20°C |
|
|